At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMNN Imunon, Inc.
Post-Mkt 12-08 17:06:47 EST
3.90
+0.00
0.00%
盘后3.92
+0.02+0.38%
16:10 EST
High4.01Low3.83Vol34.80K
Open3.90D1 Closing3.90Amplitude4.62%
Mkt Cap11.97MTradable Cap11.84MTotal Shares3.07M
T/O135.85KT/O Rate1.15%Tradable Shares3.04M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Imunon, Inc. Faces Market Volatility: The Impact of Short Selling on Stock Prices
TIPRANKS  ·  11-16
Imunon, Inc. Faces Market Volatility: The Impact of Short Selling on Stock Prices
Alliance Global Partners Remains a Buy on Imunon (IMNN)
TIPRANKS  ·  11-14
Alliance Global Partners Remains a Buy on Imunon (IMNN)
Corrected-Imunon Inc - Reports Q3 Loss per Share (Not 'EPS') $1.16
THOMSON REUTERS  ·  11-13
Corrected-Imunon Inc - Reports Q3 Loss per Share (Not 'EPS') $1.16
Imunon reports Q3 EPS ($1.16) vs ($3.76) last year
TIPRANKS  ·  11-13
Imunon reports Q3 EPS ($1.16) vs ($3.76) last year
Imunon Inc. reports third quarter net loss of $3.4 million
Reuters  ·  11-13
Imunon Inc. reports third quarter net loss of $3.4 million
Imunon Q3 EPS $(1.16) Beats $(1.80) Estimate
Benzinga  ·  11-13
Imunon Q3 EPS $(1.16) Beats $(1.80) Estimate
Imunon Inc - Reports Q3 EPS $1.16
THOMSON REUTERS  ·  11-13
Imunon Inc - Reports Q3 EPS $1.16
Imunon Launches Phase 3 Trial of IMNN-001 Immunotherapy for Ovarian Cancer
Reuters  ·  11-10
Imunon Launches Phase 3 Trial of IMNN-001 Immunotherapy for Ovarian Cancer
Imunon R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women With Ovarian Cancer
THOMSON REUTERS  ·  11-10
Imunon R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women With Ovarian Cancer
Imunon Inc expected to post a loss of $1.81 a share - Earnings Preview
Reuters  ·  11-07
Imunon Inc expected to post a loss of $1.81 a share - Earnings Preview
BRIEF-Imunon Research And Development Day: Opportunity To Hear Clinical Trial Investigators Discuss Significant Potential Of IMNN-001 To Redefine Ovarian Cancer Treatment
Reuters  ·  11-07
BRIEF-Imunon Research And Development Day: Opportunity To Hear Clinical Trial Investigators Discuss Significant Potential Of IMNN-001 To Redefine Ovarian Cancer Treatment
Imunon R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of Imnn-001 to Redefine Ovarian Cancer Treatment
THOMSON REUTERS  ·  11-07
Imunon R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of Imnn-001 to Redefine Ovarian Cancer Treatment
Imunon Inc expected to post a loss of $1.81 a share - Earnings Preview
Reuters  ·  11-03
Imunon Inc expected to post a loss of $1.81 a share - Earnings Preview
IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting
GlobeNewswire  ·  10-30
IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
GlobeNewswire  ·  10-23
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
Imunon to present Phase 3 OVATION trial of IMNN-001
TIPRANKS  ·  10-14
Imunon to present Phase 3 OVATION trial of IMNN-001
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
GlobeNewswire  ·  10-14
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
Imunon Inc. Releases Document on IL-12 Gene Therapy's Impact in Ovarian Cancer Treatment
Reuters  ·  09-22
Imunon Inc. Releases Document on IL-12 Gene Therapy's Impact in Ovarian Cancer Treatment
Imunon: OVATION 2 study results reinforce IMNN-001 efficacy benefits
TIPRANKS  ·  09-22
Imunon: OVATION 2 study results reinforce IMNN-001 efficacy benefits
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
GlobeNewswire  ·  09-22
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

Introduction

Company Name.
Imunon, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Issue price:
--